Cideciyan Artur V, Jacobson Samuel G, Ho Allen C, Krishnan Arun K, Roman Alejandro J, Garafalo Alexandra V, Wu Vivian, Swider Malgorzata, Sumaroka Alexander, Van Cauwenbergh Caroline, Russell Stephen R, Drack Arlene V, Leroy Bart P, Schwartz Michael R, Girach Aniz
Scheie Eye Institute, Department of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania.
Ophthalmol Sci. 2022 Mar 2;2(2):100133. doi: 10.1016/j.xops.2022.100133. eCollection 2022 Jun.
To understand consequences of reconstituting cone photoreceptor function in congenital binocular blindness resulting from mutations in the () gene.
Phase 1b/2 open-label, multicenter, multiple-dose, dose-escalation trial.
A homogeneous subgroup of 5 participants with light perception (LP) vision at the time of enrollment (age range, 15-41 years) selected for detailed analyses. Medical histories of 4 participants were consistent with congenital binocular blindness, whereas 1 participant showed evidence of spatial vision in early life that was later lost.
Participants received a single intravitreal injection of sepofarsen (160 or 320 μg) into the study eye.
Full-field stimulus testing (FST), visual acuity (VA), and transient pupillary light reflex (TPLR) were measured at baseline and for 3 months after the injection.
All 5 participants with LP vision demonstrated severely abnormal FST and TPLR findings. At baseline, FST threshold estimates were 0.81 and 1.0 log cd/m for control and study eyes, respectively. At 3 months, study eyes showed a large mean improvement of -1.75 log versus baseline ( < 0.001), whereas untreated control eyes were comparable with baseline. Blue minus red FST values were not different than 0 ( = 0.59), compatible with cone mediation of remnant vision. At baseline, TPLR response amplitude and latency estimates were 0.39 mm and 0.72 seconds, respectively, for control eyes, and 0.28 mm and 0.78 seconds, respectively, for study eyes. At 3 months, study eyes showed a mean improvement of 0.44 mm in amplitude and a mean acceleration of 0.29 seconds in latency versus baseline ( < 0.001), whereas control eyes showed no significant change versus baseline. Specialized tests performed in 1 participant confirmed and extended the standardized results from all 5 participants.
By subjective and objective evidence, intravitreal sepofarsen provides improvement of light sensitivity for individuals with LP vision. However, translation of increased light sensitivity to improved spatial vision may occur preferentially in those with a history of visual experience during early neurodevelopment. Interventions for congenital lack of spatial vision in -associated Leber congenital amaurosis may lead to better results if performed before visual cortex maturity.
了解在由()基因突变导致的先天性双眼失明中恢复视锥光感受器功能的后果。
1b/2期开放标签、多中心、多剂量、剂量递增试验。
入选进行详细分析的5名参与者组成的同质亚组,入组时具有光感(LP)视力(年龄范围15 - 41岁)。4名参与者的病史与先天性双眼失明一致,而1名参与者在早年有空间视觉证据,后来丧失。
参与者接受向研究眼玻璃体内单次注射司泊法森(160或320μg)。
在基线及注射后3个月测量全视野刺激测试(FST)、视力(VA)和瞬态瞳孔光反射(TPLR)。
所有5名有LP视力的参与者FST和TPLR结果均严重异常。基线时,对照眼和研究眼的FST阈值估计分别为0.81和1.0 log cd/m²。3个月时,研究眼与基线相比平均有-1.75 log的大幅改善(P < 0.001),而未治疗的对照眼与基线相当。蓝减红FST值与0无差异(P = 0.59),与残余视力的视锥介导相符。基线时,对照眼的TPLR反应幅度和潜伏期估计分别为0.39 mm和0.72秒,研究眼分别为0.28 mm和0.78秒。3个月时,研究眼与基线相比幅度平均改善0.44 mm,潜伏期平均加快0.29秒(P < 0.001),而对照眼与基线相比无显著变化。对1名参与者进行的专门测试证实并扩展了所有5名参与者的标准化结果。
根据主观和客观证据,玻璃体内注射司泊法森可提高有LP视力个体的光敏感度。然而,光敏感度增加向空间视力改善的转化可能优先发生在早期神经发育期间有视觉经验史的个体中。对于与相关的莱伯先天性黑蒙中先天性空间视力缺失的干预,如果在视觉皮层成熟之前进行,可能会产生更好的结果。